17,261 trials
Arthroplasty, Replacement, Knee · Venous Thrombosis
Primary: Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period…
Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic (VTE) Events — 86; 49; 39; 47 participants — p=<0.0001
Severe Sepsis
Primary: Mean Change in Protein C Levels From Day 1 to Day 7 — 55; 52; 79; 83 Percent Protein C Activity — p=0.011
Schizophrenia
Primary: Mean Change From Baseline in the Composite Score From the Brief Assessment of Cognition in Schizophrenia (BACS) Battery After 2 Weeks of Treatment — 0.3; 1.5 T-score…
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) Based on Independent Radiological Review for the First Intervention Period — 5.7; 5.6 months — p=0.50
Chronic Myelogenous Leukemia · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation — 30; 11; 13; 13 participants
Herpes Simplex
Primary: Pharmacokinetics of Single Dose - Tmax — 1.00; 4; 1.02 hours
Ovarian Neoplasms
Primary: Objective Response (Complete Partial, Stable and Progression) — 1; 8; 10; 20 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Overall Confirmed Response — 3; 5; 10 participants
Opiate Dependence
Primary: Slope Change From Baseline for Pupil Size — -0.5540; -0.3607; -0.1410 cm(2)/hr
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Mean Change From Baseline in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) Total Score After 4 Weeks of Treatment — -9.8…
Prostate Cancer
Primary: Number of Participants With Testosterone Level <=0.5 ng/mL From Day 28 Until the End of the Study — 94; 101; 110 participants — p=0.3022
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months…
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants